Mediwound ltd.MDWD.US Overview

US StockHealthcare

(No presentation for MDWD)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

MDWD Overall Performance

MDWD AI Analysis & Strategy

MDWD Recent Performance

1.50%

Mediwound ltd.

0.81%

Avg of Sector

-1.14%

S&P500

MDWD PowerScanner

MDWD Key Information

MDWD Valuation Metrics

MDWD Earnings Table

MDWD Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.